公开(公告)号：EP2648730A2

公开(公告)日：2013-10-16

申请号：EP11847739.7

申请日：2011-12-07

申请人： LG Life Sciences Ltd

发明人： CHUNG, Young Sik ,  PARK, Soo Ah ,  KIM, Ree Sun ,  KIM, Sung Il ,  JUHN, Jae Hyeon ,  KIM, Dong Kyu ,  KIM, Yoo Rin ,  PARK, Hee Dong ,  PARK, Seong Jae ,  LEE, Sung Hack ,  KIM, Ju Hyun ,  JUNG, Min Young

IPC分类号： A61K31/4422 ,  A61K31/41 ,  A61K9/16 ,  A61P9/00

CPC分类号： A61K9/1635 ,  A61K9/1652 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/209 ,  A61K9/2095 ,  A61K9/5084 ,  A61K31/41 ,  A61K31/4422 ,  A61K2300/00

摘要： The present invention relates to a pharmaceutical composition comprising lercanidipine hydrochloride and valsartan as active components and a method for the preparation thereof. The pharmaceutical composition comprising lercanidipine hydrochloride and valsartan according to the present invention has a superior effect on the prevention and treatment of cardiovascular diseases and their complex diseases, and reduces the adverse effects of each component. In addition, the present composition comprises lercanidipine hydrochloride and valsartan in a separated form so as to increase the dissolution rates of both components and reduce the adverse effects.

公开(公告)号：EP1851214B1

公开(公告)日：2012-09-05

申请号：EP06716026.7

申请日：2006-02-21

申请人： LG Life Sciences Ltd.

发明人： SHIN, Hyun Ik R & D Park, LG Life Sciences Ltd. ,  CHOI, Hyeong Wook R & D Park, LG Life Sciences Ltd ,  HEO, Tae Ho R & D Park, LG Life Sciences Ltd. ,  LEE, Kyu Woong R & D Park, LG Life Sciences Ltd. ,  LEE, Jae Hoon R & D Park, LG Life Sciences Ltd. ,  PARK, Ki Sook R & D Park, LG Life Sciences Ltd.

IPC分类号： C07D413/12 ,  C07D413/14 ,  C07C229/08 ,  A61K31/422 ,  A61P29/00

CPC分类号： C07C229/22 ,  C07D413/12 ,  C07D413/14

公开(公告)号：EP2178870A4

公开(公告)日：2012-04-11

申请号：EP08793298

申请日：2008-08-18

申请人： LG LIFE SCIENCES LTD

发明人： KIM SOON HA ,  KIM HYOUNG JIN ,  KOO SUN YOUNG ,  CHUNG CHUL WOONG ,  LEE SUNG BAE ,  PARK HEUI SUL ,  YOON SEUNG HYUN ,  KWAK HYO SHIN ,  SEO DONG OOK ,  PARK EOK

IPC分类号： C07D413/04 ,  A61P1/16 ,  A61P3/10 ,  A61P9/00 ,  A61P25/16 ,  A61P25/28 ,  A61P31/00 ,  A61P35/00 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D487/04 ,  C07F9/6558

CPC分类号： C07D417/06 ,  A61K31/404 ,  A61K31/416 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/497 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/675 ,  A61K45/06 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D487/04 ,  C07F9/65583 ,  C07F9/65586

摘要： The present invention relates to indole or indazole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases, comprising said indole or indazole compounds as an active ingredient.

摘要翻译： 本发明涉及可用于预防或治疗细胞坏死和坏死相关疾病的吲哚或吲唑化合物，其药学上可接受的盐或异构体。 本发明还涉及包含所述吲哚或吲唑化合物作为活性成分的用于预防或治疗细胞坏死和坏死相关疾病的方法和组合物。

公开(公告)号：EP2079710A4

公开(公告)日：2010-12-29

申请号：EP07833612

申请日：2007-10-26

申请人： LG LIFE SCIENCES LTD

发明人： CHANG HYE KYUNG ,  OH YEONG SOO ,  JANG YONG JIN ,  KIM SUNG SUB ,  MIN KYEONG SIK ,  CHUNG CHUL WOONG ,  PARK MI JEONG ,  PARK JUNG GYU

IPC分类号： C07D237/14

CPC分类号： C07D237/14

公开(公告)号：EP2220086A2

公开(公告)日：2010-08-25

申请号：EP08863947.1

申请日：2008-12-19

申请人： LG Life Sciences Ltd.

发明人： LEE, Chang-Seok ,  YIM, Hyeon Joo ,  KIM, Kyoung-Hee ,  LEE, Jaeick ,  LEE, Sung-Hack ,  LEE, Kyu Woong ,  LEE, Hee Bong ,  PARK, Wan Su ,  MIN, Changhee

IPC分类号： C07D471/04

CPC分类号： C07D471/04

摘要： Disclosed herein are novel compounds of Formula (1) as defined in the specification having excellent inhibitory activity against dipeptidyl peptidase-IV (DPP-IV), methods of preparing the same and pharmaceutical compositions comprising the same as an active agent.

公开(公告)号：EP1358198B1

公开(公告)日：2010-08-25

申请号：EP02711484.2

申请日：2002-01-18

申请人： LG Life Sciences Ltd

发明人： CHOI, Jong-Ryoo, LGCI Life Science R & D Center ,  KIM, Jeong-Min, LGCI Life Science R & D Center ,  ROH, Kee-Yoon, LGCI Life Science R & D Center ,  CHO, Dong-Gyu, LGCI Life Science R & D Center ,  LIM, Jae-Hong, LGCI Life Science R & D Center ,  HWANG, Jae-Taeg, LGCI Life Science R & D Center ,  CHO, Woo-Young, LGCI Life Science R & D Center ,  JANG, Hyun-Sook, LGCI Life Science R & D Center ,  LEE, Chang-Ho, LGCI Life Science R & D Center ,  CHOI, Tae-Saeng, LGCI Life Science R & D Center ,  KIM, Chung-Mi, LGCI Life Science R & D Center ,  KIM, Yong-Zu, LGCI Life Science R & D Center ,  KIM, Tae-Kyun, LGCI Life Science R & D Center ,  CHO, Seung-Joo, LGCI Life Science R & D Center ,  KIM, Gyoung-Won, LGCI Life Science R & D Center

IPC分类号： C07H19/10

CPC分类号： C07H19/10 ,  C07F9/65616 ,  C07H19/20

公开(公告)号：EP1583730B1

公开(公告)日：2009-08-05

申请号：EP03772907.6

申请日：2003-11-17

申请人： LG Life Sciences Ltd.

发明人： SHIN, Hyun-Ik, c/o R&D Park, LG Life Sciences Ltd. ,  CHOI, Bo-Seung, c/o R&D Park, LG Life Sciences Ltd

IPC分类号： C07C49/173 ,  C07C51/353 ,  C07C59/90 ,  C07C59/115

CPC分类号： C07C51/09 ,  C07C51/353 ,  C07C67/343 ,  C07C59/215 ,  C07C59/90 ,  C07C69/716

摘要： The present invention is related to a novel process for preparing an optically active 5-hydroxy-3-oxo-hexanoic acid derivative or its tautomer which is useful intermediate for preparing statins such as atorvastatin and rosuvastatin. Blaise reaction of (S)-4-halo-3 -hydroxybutyronitrile with -haloacetate is utilized as a key reaction to provide the product with minimal formation of side products and in good yield.

公开(公告)号：EP2079698A1

公开(公告)日：2009-07-22

申请号：EP07833615.3

申请日：2007-10-26

申请人： LG Life Sciences Ltd.

发明人： CHANG, Hye Kyung ,  OH, Yeong Soo ,  JANG, Yong Jin ,  KIM, Sung Sub ,  MIN, Kyeong Sik ,  CHUNG, Chul Woong ,  PARK, Mi Jeong ,  PARK, Jung Gyu

IPC分类号： C07D213/643 ,  C07D213/50 ,  A61K31/44 ,  A61P29/00 ,  A61P35/00

CPC分类号： C07D213/64

摘要： The present invention relates to a pyridone derivative which can be used as a caspase inhibitor, process for the preparation thereof, and pharmaceutical composition for inhibiting caspase comprising the same.

摘要翻译： 本发明涉及可用作半胱氨酸天冬氨酸蛋白酶抑制剂的吡啶酮衍生物，其制备方法和包含其的半胱天冬酶抑制药物组合物。

公开(公告)号：EP2024500A1

公开(公告)日：2009-02-18

申请号：EP07746891.6

申请日：2007-06-13

申请人： LG Life Sciences, Ltd.

发明人： KOH, Sang-seok ,  SONG, Si-young ,  KIM, Sun-a ,  LEE, Yang-soon ,  JEON, Sun-bok ,  PARK, Eui-chul ,  KIM, Young-gun

IPC分类号： C12N15/12

CPC分类号： C07K14/82

摘要： The invention relates generally to the changes in gene expression in human pancreatic adenocarcinoma. The invention relates specifically to a human gene family which is differentially expressed in cancerous pancreatic tissues compared to corresponding non-cancerous pancreatic tissues.

摘要翻译： 本发明一般涉及人胰腺腺癌中基因表达的变化。 本发明具体涉及与相应的非癌性胰腺组织相比在癌性胰腺组织中差异表达的人类基因家族。

公开(公告)号：EP1497290B1

公开(公告)日：2008-08-13

申请号：EP03715805.2

申请日：2003-04-04

申请人： LG Life Sciences Ltd.

发明人： CHOI, Hoon R & D Park, LG Life Sciences Ltd. ,  CHOI, Sang-Chul R & D Park, LG Life Sciences Ltd. ,  NAM, Do-Hyun R & D Park, LG Life Sciences Ltd. ,  CHOI, Bo-Seung R & D Park, LG Life Sciences Ltd.

IPC分类号： C07D471/04

CPC分类号： C07D471/04

摘要： The present invention relates to a process for preparing acid salts of Gemifloxacin, a quinolone type antibiotic agent having potent antimicrobial activity. The process according to the present invention can provide advantages such as simplicity of process, improvement of productivity and improvement of yield, and the like by reducing conventional three-step process to two-step process.